We’re thrilled to share a recent publication on Siranomics, Inc. and Sagesse Bio's siRNA injectable when used for targeted local fat reduction. Results yielded positive results showing a notable decrease in adipocyte volume and lipid content. Read more below!
Sagesse Bio
Biotechnology Research
Delivering innovative and life changing therapies to patients with an initial emphasis on focal fat destruction.”
About us
Sagesse Bio is an early stage pharmaceutical company utilizing RNAi technology to accelerate the clinical development of novel solutions to destroy or remodel undesirable pockets of fat. The company's lead compound, SGY-101, is IND-enabled and currently in Phase II clinical trials for other indications. Sagesse Bio will promptly begin clinical evaluation of SGY-101 with comprehensive scientific and technical support from Sirnaomics which specializes in the development of RNAi technology. Initial indications of interest include body contouring and fat reduction. The strategic goal of Sagesse Bio is to become the leading provider of therapeutic solutions for targeted fat reduction in both medical dermatology and aesthetic medicine.
- Website
-
www.sagessebio.com
External link for Sagesse Bio
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Type
- Privately Held
- Founded
- 2024
Employees at Sagesse Bio
Updates
-
Sagesse Bio is extremely excited to partner with industry leaders to advance SGY-101, a novel siRNA therapeutic for focal fat reduction and tissue remodeling, into clinical trials https://lnkd.in/gbqWwiJc
-
Sagesse Bio is excited to leverage Gore Range Capital's skin health expertise and SIRNAOMICS advanced RNAi technology to develop innovative therapeutic solutions for fat reduction in dermatology and aesthetic medicine. https://lnkd.in/gKTrtA_a
-
Sagesse Bio is an early stage pharmaceutical company utilizing RNAi technology to accelerate the clinical development of novel solutions to destroy or remodel undesirable pockets of fat. The company's lead compound, SGY-101, is IND-enabled and currently in Phase II clinical trials for other indications. Sagesse Bio will promptly begin clinical evaluation of SGY-101 with comprehensive scientific and technical support from Sirnaomics which specializes in the development of RNAi technology. Initial indications of interest include body contouring and fat reduction. The strategic goal of Sagesse Bio is to become the leading provider of therapeutic solutions for targeted fat reduction in both medical dermatology and aesthetic medicine.